Kabeer Aziz

Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York.

Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Quantoom Biosciences SA is a Belgian company that is focused on revolutionizing mRNA production through the development of their platform, ntensify. The private company is based in Nivelles, Belgium. This platform includes DNA amplification and RNA manufacturing, with the ntensify systems being the core of their RNA production technology. The company is made up of a team of scientists, engineers, and clinicians who are dedicated to addressing the major challenges in DNA and RNA production for vaccines and therapeutics.

Frontier Nutrition, Inc. develops and manufactures fortified packaged food. Its recipes are localized for traditional diets, taste, and nutrition. The company was founded by Eddie Bearnot and Tanveer Ali on August 18, 2016 and is headquartered in DE.

Univercells SA designs single-use cost-efficient bioprocess solutions to open the next chapter in bio manufacturing. The company was founded by Jose Castillo, Guillaume De Viron and Hugues Bultot in 2013 and is headquartered in Gosselies, Belgium.

LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023.

Global Health Investment Fund seeks investment opportunities in global health technologies. The fund invests in new drugs & vaccines, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications. It provides financing in the form of mezzanine for later-stage capital requirements.